All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F19%3A00504092" target="_blank" >RIV/67985823:_____/19:00504092 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11310/19:10404622 RIV/00023001:_____/19:00077699

  • Result on the web

    <a href="https://doi.org/10.3389/fphar.2019.00159" target="_blank" >https://doi.org/10.3389/fphar.2019.00159</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3389/fphar.2019.00159" target="_blank" >10.3389/fphar.2019.00159</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats

  • Original language description

    Epoxyeicosatrienoic acids (EETs) and their analogs have been identified as potent antihypertensive compounds with cardio-and renoprotective actions. Here, we examined the effect of EET-A, an orally active EET analog, and c-AUCB, an inhibitor of the EETs degrading enzyme soluble epoxide hydrolase, on the progression of postmyocardial infarction (MI) heart failure (HF) in normotensive Hannover Sprague-Dawley (HanSD) and in heterozygous Ren-2 transgenic rats (TGR) with angiotensin II-dependent hypertension. Adult male rats (12 weeks old) were subjected to 60-min left anterior descending (LAD) coronary artery occlusion or sham (non-MI) operation. Animals were treated with EET-A and c-AUCB (10 and 1 mg/kg/day, respectively) in drinking water, given alone or combined for 5 weeks starting 24 h after MI induction. Left ventricle (LV) function and geometry were assessed by echocardiography before MI and during the progression of HF. At the end of the study, LV function was determined by catheterization and tissue samples were collected. Ischemic mortality due to the incidence of sustained ventricular fibrillation was significantly higher in TGR than in HanSD rats (35.4 and 17.7%, respectively). MI-induced HF markedly increased LV end-diastolic pressure (Ped) and reduced fractional shortening (FS) and the peak rate of pressure development [C (dP/dt) max] in untreated HanSD compared to sham (non-MI) group [Ped: 30.5 +/- 3.3 vs. 9.7 +/- 1.3 mmHg, FS: 11.1 +/- 1.0 vs. 40.8 +/- 0.5%, C (dP/dt) max: 3890 +/- 291 vs. 5947 +/- 309 mmHg/s]. EET-A and c-AUCB, given alone, tended to improve LV function parameters in HanSD rats. Their combination amplified the cardioprotective effect of single therapy and reached significant differences compared to untreated HanSD controls [Ped: 19.4 +/- 2.2 mmHg, FS: 14.9 +/- 1.0%, C (dP/dt) max: 5278 +/- 255 mmHg/s]. In TGR, MI resulted in the impairment of LV function like HanSD rats. All treatments reduced the increased level of albuminuria in TGR compared to untreated MI group, but neither single nor combined EET-based therapy improved LV function. Our results indicate that EET-based therapy attenuates the progression of post-MI HF in HanSD, but not in TGR, even though they exhibited renoprotective action in TGR hypertensive rats.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30105 - Physiology (including cytology)

Result continuities

  • Project

    <a href="/en/project/NV15-27735A" target="_blank" >NV15-27735A: Progression of chronic heart failure and cardiorenal syndrome in hypertensive rats after myocardial infarction: role of epoxyeicosatrienoic acids.</a><br>

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2019

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Frontiers in Pharmacology

  • ISSN

    1663-9812

  • e-ISSN

  • Volume of the periodical

    10

  • Issue of the periodical within the volume

    Mar 1

  • Country of publishing house

    CH - SWITZERLAND

  • Number of pages

    12

  • Pages from-to

    159

  • UT code for WoS article

    000459963300001

  • EID of the result in the Scopus database